NASDAQ:HOOK - Hookipa Pharma Stock Price, Forecast & News

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.45) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.66) by $0.21. The company earned $2.04 million during the quarter, compared to the consensus estimate of $2.35 million. View Hookipa Pharma's Earnings History.

Hookipa Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Hookipa Pharma.

5 Wall Street analysts have issued 12-month target prices for Hookipa Pharma's stock. Their forecasts range from $15.00 to $23.00. On average, they expect Hookipa Pharma's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price. View Analyst Price Targets for Hookipa Pharma.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hookipa Pharma.

Media headlines about HOOK stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Hookipa Pharma earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Hookipa Pharma.

Hookipa Pharma saw a decline in short interest in January. As of January 31st, there was short interest totalling 196,700 shares, a decline of 33.9% from the January 15th total of 297,700 shares. Based on an average daily trading volume, of 105,200 shares, the short-interest ratio is presently 1.9 days. Currently, 1.7% of the shares of the stock are short sold. View Hookipa Pharma's Current Options Chain.

Some companies that are related to Hookipa Pharma include Dermira (DERM), Phathom Pharmaceuticals (PHAT), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Gossamer Bio (GOSS), Kiniksa Pharmaceuticals (KNSA), I-Mab (ARQT), Myovant Sciences (MYOV), Achillion Pharmaceuticals (ACHN), Applied Therapeutics (APLT), Cytokinetics (CYTK), Radius Health (RDUS), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH) and ImmunoGen (IMGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Pfizer (PFE), Exxon Mobil (XOM), Alector (ALEC), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Verizon Communications (VZ), Akero Therapeutics (AKRO) and Axsome Therapeutics (AXSM).

(HOOK) raised $100 million in an initial public offering on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Kempen was co-manager.

Hookipa Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (2.27%), Geode Capital Management LLC (0.48%), State Street Corp (0.43%), Bank of New York Mellon Corp (0.13%), Charles Schwab Investment Management Inc. (0.10%) and UBS Group AG (0.06%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr. View Institutional Ownership Trends for Hookipa Pharma.

HOOK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Bank of America Corp DE. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky and Klaus Orlinger. View Insider Buying and Selling for Hookipa Pharma.

HOOK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Geode Capital Management LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, UBS Group AG, Barclays PLC and American International Group Inc.. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker and Sofinnova Capital Vi Fcpr. View Insider Buying and Selling for Hookipa Pharma.

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HOOK stock can currently be purchased for approximately $11.81.

Hookipa Pharma has a market capitalization of $254.97 million. Hookipa Pharma employs 56 workers across the globe.View Additional Information About Hookipa Pharma.

The official website for Hookipa Pharma is http://www.hookipapharma.com/.

Hookipa Pharma's mailing address is 350 Fifth Avenue 72nd Floor Suite 7240, New York NY, 10118. The company can be reached via phone at 431-890-6360 or via email at [email protected]